

NUPATHE INC.
Form 8-K
October 19, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 19, 2010

NuPathe Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other Jurisdiction of
Incorporation)

001-34836

(Commission File Number)

20-2218246

(IRS Employer Identification No.)

227 Washington Street

Suite 200

Conshohocken, Pennsylvania

(Address of Principal Executive Offices)

19428

(Zip Code)

Registrant's telephone number, including area code: **(484) 567-0130**

Not Applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On October 19, 2010, NuPathe Inc.® issued a press release announcing certain top-line results from a 12 month open-label, safety trial for Zelrix™, as well as the development of an *in vitro* analytical testing method for Zelrix. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following press release is furnished as Exhibit 99.1 to this Form 8-K pursuant to Item 7.01 and shall not be deemed to be “filed”:

99.1 Press release, dated October 19, 2010, issued by NuPathe Inc.

- 2 -

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NUPATHE INC.

By: /s/ Keith A. Goldan

Keith A. Goldan

Chief Financial Officer

Dated: October 19, 2010

- 3 -

3

EXHIBIT INDEX

Exhibit No.	Description of Exhibit
99.1	Press release, dated October 19, 2010, issued by NuPathe Inc.